Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by ScienceFirston Mar 28, 2023 1:02pm
249 Views
Post# 35364912

88% TR and 70% CR @90-days without 10 of the 12 undertreated

88% TR and 70% CR @90-days without 10 of the 12 undertreatedThe chart on the ASCO-GU poster allows us to assess what would have been a CR @90-days without the last 10 "red" ones at the bottom of the chart.

https://theralase.com/wp-content/uploads/2023/02/2023-GU-ASCO-Poster-Presentation-02-01-2023.jpg

We would have add 33 evaluable patients (instead of 43 ones):  

23 CR
6 IR

for a TR of 88% (29/33)
for a CR of 70% (23/33)

A very good chance to take to delay any cystectomy and maybe take a chance to even have a durable response.
<< Previous
Bullboard Posts
Next >>